Ottery FD - Search Results

1

Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies.

Kagan R, Cano A, Nappi RE, English ML, Mancuso S, Wu X, Ottery FD. Kagan R, et al. Among authors: ottery fd. Adv Ther. 2024 Dec 30. doi: 10.1007/s12325-024-03073-8. Online ahead of print. Adv Ther. 2024. PMID: 39739195

2

Translation, cultural adaptation, and assessment of the linguistic and content validity of the PG-SGA to the Spanish linguistic setting by cancer patients and healthcare professionals.

Fuchs-Tarlovsky V, Velasco Gimeno C, Arias-Soberón MD, Silva-Sánchez C, Álvarez-Altamirano K, Vedenne-Gutierrez F, Bejarano-Rosales MP, Motilla de la Cámara M, Castillo-Cruz J, Cuerda Compés C, Ottery FD, Jager-Wittenaar H. Fuchs-Tarlovsky V, et al. Among authors: ottery fd. Nutrition. 2024 Dec;128:112567. doi: 10.1016/j.nut.2024.112567. Epub 2024 Aug 28. Nutrition. 2024. PMID: 39366302

3

Totality of evidence refutes neoplasm risk with fezolinetant.

Neal-Perry G, Santoro N, Cano A, Nappi RE, Shapiro M, Ottery FD. Neal-Perry G, et al. Among authors: ottery fd. Lancet. 2024 May 18;403(10440):1987-1988. doi: 10.1016/S0140-6736(24)00709-8. Lancet. 2024. PMID: 38762322 No abstract available.

4

Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause.

Shapiro C M M, Cano A, Nappi RE, Santoro N, English ML, Mancuso S, Morga A, Siddiqui E, Valluri U, Ottery FD. Shapiro C M M, et al. Among authors: ottery fd. Maturitas. 2024 Aug;186:107999. doi: 10.1016/j.maturitas.2024.107999. Epub 2024 May 15. Maturitas. 2024. PMID: 38749864 Free article. Clinical Trial.

5

Swedish translation and cultural adaptation of the scored Patient-Generated Subjective Global Assessment (PG-SGA©)-A validated tool for screening and assessing malnutrition in clinical practice and research.

Lindström R, Orrevall Y, Belqaid K, McGreevy J, Ottenblad A, Rothenberg E, Slinde F, Ottery FD, Jager-Wittenaar H, Einarsson S. Lindström R, et al. Among authors: ottery fd. Scand J Caring Sci. 2024 Sep;38(3):589-601. doi: 10.1111/scs.13267. Epub 2024 May 7. Scand J Caring Sci. 2024. PMID: 38713754

6

Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2).

Nappi RE, Johnson KA, Stute P, Blogg M, English M, Morga A, Scrine L, Siddiqui E, Ottery FD. Nappi RE, et al. Among authors: ottery fd. Menopause. 2024 Jun 1;31(6):512-521. doi: 10.1097/GME.0000000000002354. Epub 2024 Apr 16. Menopause. 2024. PMID: 38626380 Free article. Clinical Trial.

7

Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2).

Santoro N, Nappi RE, Neal-Perry G, English M, King DD, Yamaguchi Y, Ottery FD. Santoro N, et al. Among authors: ottery fd. Menopause. 2024 Apr 1;31(4):247-257. doi: 10.1097/GME.0000000000002340. Menopause. 2024. PMID: 38517210 Clinical Trial.

8

Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials.

Cano A, Nappi RE, Santoro N, Stute P, Blogg M, English ML, Morga A, Scrine L, Siddiqui E, Ottery FD. Cano A, et al. Among authors: ottery fd. BJOG. 2024 Aug;131(9):1296-1305. doi: 10.1111/1471-0528.17773. Epub 2024 Feb 6. BJOG. 2024. PMID: 38320967 Free article. Clinical Trial.

9

Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.

Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, Thurston RC, English M, Franklin C, Lee M, Neal-Perry G. Lederman S, et al. Among authors: ottery fd. Lancet. 2023 Apr 1;401(10382):1091-1102. doi: 10.1016/S0140-6736(23)00085-5. Epub 2023 Mar 13. Lancet. 2023. PMID: 36924778 Clinical Trial.

10

Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.

Neal-Perry G, Cano A, Lederman S, Nappi RE, Santoro N, Wolfman W, English M, Franklin C, Valluri U, Ottery FD. Neal-Perry G, et al. Among authors: ottery fd. Obstet Gynecol. 2023 Apr 1;141(4):737-747. doi: 10.1097/AOG.0000000000005114. Epub 2023 Mar 9. Obstet Gynecol. 2023. PMID: 36897180 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters